Relationship of C-Reactive Protein With Clinical Response After Therapy With Ustekinumab in Crohn's Disease

Abstract

The potential benefit of ustekinumab in CD is supported by serum CRP reductions. Evidence suggests that increased systemic inflammation as manifested by higher baseline CRP values leads to larger treatment effects with ustekinumab, especially in infliximab-experienced patients.